EphA2 silencing promotes growth, migration, and metastasis in salivary adenoid cystic carcinoma: In vitro and in vivo study

American Journal of Translational Research

Volumn 8, Issue 3, 2016, Pages 1518-1529

  Wang, Meng ^a   Zhao, Xiao Ping ^b   Xu, Zhi ^a   Yan, Ting Lin ^a   Song, Yong ^c   Song, Kai ^d   Huang, Chun Ming ^a   Wang, Lin ^a   Zhou, Xiao Cheng ^a   Jiang, Er Hui ^a   Shao, Zhe ^a   Shang, Zheng Jun ^a  

^a WUHAN UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c Liuzhou People's Hospital   (China)

^d QINGDAO UNIVERSITY   (China)

Author keywords

EphA2; Perineural invasion; RNA interference; Salivary adenoid cystic carcinoma; Tumor progression

Indexed keywords

EPHRIN RECEPTOR A2; TRANSCRIPTION FACTOR SLUG; UVOMORULIN;

ADENOID CYSTIC CARCINOMA; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL INVASION ASSAY; CELL MIGRATION; CELL MIGRATION ASSAY; CELL PROLIFERATION ASSAY; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; METASTASIS; MOUSE; NONHUMAN; PERINEURAL INVASION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; WESTERN BLOTTING;

EID: 84964490269     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Matsuba HM, Spector GJ, Thawley SE, Simpson JR, Mauney M and Pikul FJ. Adenoid cystic salivary gland carcinoma: A histopathologic review of treatment failure patterns. Cancer 1986; 57: 519-524.
2. Barrett AW and Speight PM. Perineural invasion in adenoid cystic carcinoma of the salivary glands: a valid prognostic indicator? Oral Oncol 2009; 45: 936-940.
3. Mitani Y, Liu B, Rao PH, Borra VJ, Zafereo M, Weber RS, Kies M, Lozano G, Futreal PA, Caulin C and El-Naggar AK. Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations. Clin Cancer Res 2016; 22: 725-733.
4. Sung MW, Kim KH, Kim JW, Min YG, Seong WJ, Roh JL, Lee SJ, Kwon TK and Park SW. Clinicopathologic predictors and impact of distant metastasis from adenoid cystic carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2003; 129: 1193-1197.
5. van der Wal JE, Becking AG, Snow GB and van der Waal I. Distant metastases of adenoid cystic carcinoma of the salivary glands and the value of diagnostic examinations during follow-up. Head Neck 2002; 24: 779-783.
6. Spiro RH and Huvos AG. Stage means more than grade in adenoid cystic carcinoma. Am J Surg 1992; 164: 623-628.
7. Pasquale EB. Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol 2005; 6: 462-475.
8. Adams RH and Eichmann A. Axon guidance molecules in vascular patterning. Cold Spring Harb Perspect Biol 2010; 2: a001875.
9. Gelfand MV, Hong S and Gu C. Guidance from above: common cues direct distinct signaling outcomes in vascular and neural patterning. Trends Cell Biol 2009; 19: 99-110.
10. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010; 10: 165-180.
11. Wykosky J and Debinski W. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res 2008; 6: 1795-1806.
12. Zhuang G, Brantley-Sieders DM, Vaught D, Yu J, Xie L, Wells S, Jackson D, Muraoka-Cook R, Arteaga C and Chen J. Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab Therapy. Cancer Res 2009; 70: 299-308.
13. Shao Z, Zhu F, Song K, Zhang H, Liu K and Shang Z. EphA2/ephrinA1 mRNA expression and protein production in adenoid cystic carcinoma of salivary gland. J Oral Maxillofac Surg 2013; 71: 869-878.
14. Shi H, Wang J, Dong F, Wang X, Li H and Hou Y. The effect of proteoglycans inhibited by RNA interference on metastatic characters of human salivary adenoid cystic carcinoma. BMC Cancer 2009; 9: 456.
15. Batlle E, Bacani J, Begthel H, Jonkheer S, Gregorieff A, van de Born M, Malats N, Sancho E, Boon E, Pawson T, Gallinger S, Pals S and Clevers H. EphB receptor activity suppresses colorectal cancer progression. Nature 2005; 435: 1126-1130.
16. Brantley-Sieders DM, Fang WB, Hicks DJ, Zhuang G, Shyr Y and Chen J. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J 2005; 19: 1884-1886.
17. Guo H, Miao H, Gerber L, Singh J, Denning MF, Gilliam AC and Wang B. Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin. Cancer Res 2006; 66: 7050-7058.
18. Huang J, Xiao D, Li G, Ma J, Chen P, Yuan W, Hou F, Ge J, Zhong M, Tang Y, Xia X and Chen Z. EphA2 promotes epithelial-mesenchymal transition through the Wnt/beta-catenin pathway in gastric cancer cells. Oncogene 2014; 33: 2737-2747.
19. Herath NI, Doecke J, Spanevello MD, Leggett BA and Boyd AW. Epigenetic silencing of EphA1 expression in colorectal cancer is correlated with poor survival. Br J Cancer 2009; 100: 1095-1102.
20. Chiu ST, Chang KJ, Ting CH, Shen HC, Li H and Hsieh FJ. Over-expression of EphB3 enhances cell-cell contacts and suppresses tumor growth in HT-29 human colon cancer cells. Carcinogenesis 2009; 30: 1475-1486.
21. Miao H, Wei BR, Peehl DM, Li Q, Alexandrou T, Schelling JR, Rhim JS, Sedor JR, Burnett E and Wang B. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol 2001; 3: 527-530.
22. Lu M, Miller KD, Gokmen-Polar Y, Jeng MH and Kinch MS. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. Cancer Res 2003; 63: 3425-3429.
23. Parri M, Taddei ML, Bianchini F, Calorini L and Chiarugi P. EphA2 reexpression prompts invasion of melanoma cells shifting from mesenchymal to amoeboid-like motility style. Cancer Res 2009; 69: 2072-2081.
24. Udayakumar D, Zhang G, Ji Z, Njauw CN, Mroz P and Tsao H. EphA2 is a critical oncogene in melanoma. Oncogene 2011; 30: 4921-4929.
25. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR and Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 2001; 61: 2301-2306.
26. Noblitt LW, Bangari DS, Shukla S, Knapp DW, Mohammed S, Kinch MS and Mittal SK. Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Cancer Gene Ther 2004; 11: 757-766.
27. Dopeso H, Mateo-Lozano S, Mazzolini R, Rodrigues P, Lagares-Tena L, Ceron J, Romero J, Esteves M, Landolfi S, Hernandez-Losa J, Castano J, Wilson AJ, Ramon y Cajal S, Mariadason JM, Schwartz S Jr. and Arango D. The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis. Cancer Res 2009; 69: 7430-7438.
28. Miao H, Strebhardt K, Pasquale EB, Shen TL, Guan JL and Wang B. Inhibition of integrin-mediated cell adhesion but not directional cell migration requires catalytic activity of EphB3 receptor tyrosine kinase. Role of Rho family small GTPases. J Biol Chem 2005; 280: 923-932.
29. Noren NK, Foos G, Hauser CA and Pasquale EB. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol 2006; 8: 815-825.
30. Miura K, Nam JM, Kojima C, Mochizuki N and Sabe H. EphA2 engages Git1 to suppress Arf6 activity modulating epithelial cell-cell contacts. Mol Biol Cell 2009; 20: 1949-1959.
31. Zantek ND, Azimi M, Fedor-Chaiken M, Wang B, Brackenbury R and Kinch MS. E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ 1999; 10: 629-638.